Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
New Equilibrium Biosciences has developed a computational–experimental platform to discover lead drug candidates that regulate intrinsically disordered proteins implicated in cancers and neurodegenerative disorders. The company says that about 30% of proteins are predicted to not have a single 3D structure. Instead, they have evolved to fluctuate between an ensemble of short-lived conformations, which enable […]
Rome Therapeutics was founded to develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome. The repeatome makes up 60% of our genome and consists of repetitive sequences of nucleic acids, known as repeats. These repeats have long been dismissed as “junk DNA.” Much of […]
Allozymes is applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. The company’s first target application is to transform ingredients manufacturing for industries ranging from pharmaceuticals and cosmetics to food and beverages. Allozymes says it is capable achieving 10X faster and cheaper enzyme development with 200X higher chance of success and 1,000,000X less […]